LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.47 1.65

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.4

Max

2.51

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
Verkoop	586K 718K
EPS	-0.125
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-5.5M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+118.44% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-25M 458M
Vorige openingsprijs	0.82
Vorige sluitingsprijs	2.47

Nieuwssentiment

By Acuity

50%

155 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 mei 2026, 16:33 UTC

Winsten

Belangrijke Marktbewegers

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mei 2026, 21:10 UTC

Winsten

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 19:47 UTC

Winsten

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mei 2026, 19:17 UTC

Marktinformatie

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mei 2026, 19:10 UTC

Marktinformatie

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mei 2026, 18:38 UTC

Marktinformatie

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mei 2026, 18:35 UTC

Acquisities, Fusies, Overnames

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mei 2026, 18:09 UTC

Marktinformatie

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mei 2026, 17:58 UTC

Marktinformatie

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mei 2026, 17:54 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

22 mei 2026, 17:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 mei 2026, 17:54 UTC

Marktinformatie

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mei 2026, 17:03 UTC

Marktinformatie

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mei 2026, 16:54 UTC

Marktinformatie

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

22 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 16:16 UTC

Marktinformatie

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 mei 2026, 15:55 UTC

Marktinformatie

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mei 2026, 15:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 mei 2026, 15:42 UTC

Marktinformatie

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mei 2026, 15:35 UTC

Marktinformatie

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

118.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD 118.44%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

155 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.